Clinical trials: Cephalalgia
Migraine
Machine Learning Assessment of Next-Day Migraine Likelihood
Development of a machine learning (ML) algorithm for assessment of next-day migraine likelihood, drawing on self-reported migraine-related information, and geographic location, collected via the Nerivio app- a mobile application…
- Trial name
- NCT07227194
- Where
- United States
- Volunteers
- 53,065 people
- Sponsor
- Theranica
Migraine
A Study of 3 Dosage Strengths of Almotriptan Malate (AXERT®) in the Treatment of Acute Migraine in Adolescents
The purpose of this study is to evaluate the effectiveness and safety of almotriptan malate (AXERT®) in treating acute migraine headaches in adolescents.
- Trial name
- NCT00210483
- Testing
- almotriptan malate
- Volunteers
- 866 people
- Sponsor
- Janssen-Ortho LLC
Migraine Disorders
Migraine Study in Adolescent Patients
This study was designed to determine how well the combination medication, sumatriptan and naproxen sodium, treats migraine headache in adolescents 12-17 years old
- Trial name
- NCT00843024
- Testing
- Sumatriptan and Naproxen Sodium
- Where
- 79 sites in United States
- Volunteers
- 589 people
- Sponsor
- GlaxoSmithKline
Migraine
Nerivio Efficacy Under High-Frequency Use
This is a Post-marketing study investigating the impact of frequant usage with Nerivio on the safety profile of Remote Electrical Neuromodulation (REN) for the treatment of migraine.
- Trial name
- NCT07336056
- Testing
- Nerivio (REN device)
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Theranica
Episodic Migraine
A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine
The main purpose of this study is to evaulate the efficacy and safety of galcanezumab in participants 6 to 17 years of age for the preventive treatment of episodic migraine.
- Trial name
- REBUILD-1 (NCT03432286)
- Testing
- Galcanezumab
- Where
- 73 sites in United States, Denmark and 8 more
- Volunteers
- 533 people
- Sponsor
- Eli Lilly and Company
Migraine
Influence of a Dietary Supplement as Treatment of Migraine in Children and Adolescents
Migraine in children and adolescents can be associated with low serum levels of coenzyme q10, the key-enzyme of mitochondrial energy production.During migraine attacks inflammation is an important issue.
- Trial name
- NCT01010711
- Testing
- Migra 3
- Where
- 2 sites in Germany
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- Complen Health GmbH
Primary Headache Disorder
Feasibility of a Developmentally-tailored Mobile App for Tracking Mood and Pain in Children With Migraine
This study aims to inform the continued development of a mobile app intended to support the treatment of CYP with migraine. After extensive public and patient involvement, Happyr Health has developed a mobile app that allows…
- Trial name
- NCT05337930
- Testing
- Happyr App
- Where
- United Kingdom
- Sponsor
- Happyr Ltd
Migraine With Aura, Migraine Without Aura
Migraine With and Without Aura Characteristics and Response to Remote Electrical Neuromodulation (REN) Treatment
This is a Post-marketing, real-world evidence study investigating the safety and efficacy of the acute treatment of migraine with a Remote Electrical Neuromodulation (REN) device (Nerivio) in migraine patients with and without…
- Trial name
- NCT06023953
- Testing
- Nerivio device
- Where
- Israel
- Volunteers
- 31,715 people
- Sponsor
- Theranica
Acute Treatment of Migraine
A Study to Learn About the Study Medicine Called Zavegepant (PF-07930207) in Children With a History of Migraine
The purpose of the study is to learn about safety and how the body processes the study medicine called Zavegepant (PF-07930207) in children with a history of migraine.
- Trial name
- NCT06995729
- Testing
- Zavegepant
- Where
- 14 sites in United States
- Volunteers
- 16 people
- Sponsor
- Pfizer
Chronic Migraine
A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine
The main purpose of this study is to evaluate the efficacy and safety of galcanezumab for the preventive treatment of chronic migraine in participants 12 to 17 years of age.
- Trial name
- REBUILD-2 (NCT04616326)
- Testing
- Galcanezumab
- Where
- 88 sites in United States, Denmark and 9 more
- Volunteers
- 312 people
- Sponsor
- Eli Lilly and Company
Migraine
Efficacy and Safety of Erenumab in Pediatric Participants With Episodic Migraine
This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to <12 years) and adolescents (12 to <18 years) with episodic migraine.
- Trial name
- OASIS(EM) (NCT03836040)
- Testing
- Erenumab Dose 1, Erenumab Dose 2, Erenumab Dose 3
- Where
- 11 sites in United States, Belgium and 2 more
- Volunteers
- 457 people
- Sponsor
- Amgen
Migraine
A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine
The purpose of this study is to learn about the effect of a study medicine called rimegepant in adolescents who have frequent migraine attacks. Rimegepant is a tablet that disintegrates when you put it on or under your tongue.
- Trial name
- NCT06616194
- Testing
- Rimegepant
- Where
- 102 sites in United States, Canada and 10 more
- Volunteers
- 636 people
- Sponsor
- Pfizer
Migraine, Acute Treatment of Migraine
Nerivio Long-term Usage in Patients With Migraine
This is a post-marketing real-world evidence study investigates long-term treatment with the Remote Electrical Neuromodulation (REN) wearable Nerivio device over 3 consecutive years in patients with migraine.
- Trial name
- NCT06738056
- Testing
- Nerivio
- Where
- United States
- Volunteers
- 244 people
- Sponsor
- Theranica
Migraine, Vascular Headaches
A Study of the Effectiveness and Safety of Topiramate for the Prevention of Migraine Attacks in Children
The primary purpose of this study is to evaluate the effectiveness and safety of topiramate compared with placebo in the prevention of migraine attacks in children (12 to 17 years of age).
- Trial name
- NCT00210535
- Volunteers
- 110 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Pediatric Migraine
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
The purpose of this study is to test the safety and efficacy of BHV-3000 versus placebo in the acute treatment of moderate or severe migraine in children and adolescents.
- Trial name
- NCT04649242
- Testing
- Rimegepant/BHV3000
- Where
- 246 sites in United States, Canada and 7 more
- Volunteers
- 2,100 people
- Sponsor
- Pfizer
Cluster Headache
Data Collection on the ATI Neurostimulation System: SPG Stimulation for Cluster Headache
The primary objectives of the Registry are to: 1. Monitor the transfer of the ATI Neurostimulation System and its safety/clinical performance to a larger number of centers in the post market phase and 2.
- Trial name
- NCT01677026
- Where
- 11 sites in Denmark, Germany
- Volunteers
- 150 people
- Sponsor
- Autonomic Technologies, Inc.
Migraine
Efficacy of Zolmitriptan (Zomig) in the Treatment of Migraines in Adolescents
The purpose of this study is to evaluate the effectiveness and safety of Zolmitriptan (Zomig) nasal spray, 5.0 mg, compared with placebo (inactive drug) for 2 migraine headaches over a 3-month period in adolescent patients (aged…
- Trial name
- NCT00617695
- Testing
- Zolmitriptan
- Volunteers
- 247 people
- Sponsor
- Impax Laboratories, LLC
Migraine
A Prospective Post-marketing Observational Study Assessing the Safety and Efficacy of Nerivio for Migraine Prevention.
Nerivio is a remote electrical neuromodulation (REN) device that is FDA-cleared for migraine prevention (as well as for acute treatment of migraine), in individuals 12 and older.
- Trial name
- NCT05940870
- Testing
- Nerivio
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Theranica
Migraine
A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Years of Age
The primary objective of the study is to evaluate the efficacy of fremanezumab as compared to placebo for the preventive treatment of episodic migraine (EM).
- Trial name
- NCT04458857
- Testing
- Fremanezumab
- Where
- 89 sites in United States, Canada and 7 more
- Volunteers
- 235 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Migraine Disorders, Headache Disorders
Therapy for Migraine Prevention in Children 6-11 Years of Age
The aim of this study is to evaluate the effect of SPN-538 for the prophylaxis of migraine in pediatric patients 6 to 11 years old.
- Trial name
- NCT04050293
- Testing
- SPN-538
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Supernus Pharmaceuticals, Inc.